Literature DB >> 11090796

Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II.

J A de Lemos1, E M Antman, R P Giugliano, D A Morrow, C H McCabe, S S Cutler, A Charlesworth, R Schröder, E Braunwald.   

Abstract

Determination of ST-segment resolution 60 minutes after the administration of thrombolytic therapy allows accurate risk stratification for mortality and congestive heart failure. Patients with complete ST resolution at 60 minutes tended to be at lower risk for 30-day mortality than patients with complete ST resolution at 90 minutes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090796     DOI: 10.1016/s0002-9149(00)01207-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  New support for clarifying the relation between ST segment resolution and microvascular function: degree of ST segment resolution correlates with the pressure derived collateral flow index.

Authors:  M Sezer; Y Nisanci; B Umman; E Yilmaz; A Olcay; F Erzengin; O Ozsaruhan
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

2.  [Prediction of outcome in ST elevation myocardial infarction by the extent of ST segment deviation recovery. Which method is best?].

Authors:  K Schröder; U Zeymer; W Wegschneider; R Schröder
Journal:  Z Kardiol       Date:  2004-08

Review 3.  Role of Sam68 as an adaptor protein in signal transduction.

Authors:  S Najib; C Martín-Romero; C González-Yanes; V Sánchez-Margalet
Journal:  Cell Mol Life Sci       Date:  2005-01       Impact factor: 9.261

Review 4.  Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.

Authors:  Michael A Morse; Josh W Todd; George A Stouffer
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

5.  ST-segment resolution prior to primary percutaneous coronary intervention is a poor indicator of coronary artery patency in patients with acute myocardial infarction.

Authors:  Niels J Verouden; Joost D Haeck; Karel T Koch; José P Henriques; Jan Baan; René J van der Schaaf; Marije M Vis; Ron J Peters; Arthur A Wilde; Jan J Piek; Jan G Tijssen; Robbert J de Winter
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

6.  Serum NT-proBNP on admission can predict ST-segment resolution in patients with acute myocardial infarction after primary percutaneous coronary intervention.

Authors:  Bin Peng; Hao Xia; Aihua Ni; Gang Wu; Xuejun Jiang
Journal:  Herz       Date:  2015-05-22       Impact factor: 1.443

7.  One year results of the Middlesbrough early revascularisation to limit infarction (MERLIN) trial.

Authors:  A G C Sutton; P G Campbell; R Graham; D J A Price; J C Gray; E D Grech; J A Hall; A A Harcombe; R A Wright; R H Smith; J J Murphy; A Shyam-Sundar; M J Stewart; A Davies; N J Linker; M A de Belder
Journal:  Heart       Date:  2005-10       Impact factor: 5.994

8.  aVR ST elevation: an important but neglected sign in ST elevation acute myocardial infarction.

Authors:  Cheuk-Kit Wong; Wanzhen Gao; Ralph A H Stewart; Jocelyne Benatar; John K French; Philip E G Aylward; Harvey D White
Journal:  Eur Heart J       Date:  2010-05-31       Impact factor: 29.983

9.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

10.  ST-segment resolution as a marker for severe myocardial fibrosis in ST-segment elevation myocardial infarction.

Authors:  Qian Dong; Xuesong Wen; Guanglei Chang; Rui Xia; Sihang Wang; Yunjing Yang; Yi Tao; Dongying Zhang; Shu Qin
Journal:  BMC Cardiovasc Disord       Date:  2021-09-21       Impact factor: 2.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.